Folate based radiopharmaceuticals for imaging and therapy of cancer and inflammation

Current Pharmaceutical Design

Volumn 18, Issue 8, 2012, Pages 1058-1083

  Müller, Cristina ^a  

^a ETH Zurich   (Switzerland)

Author keywords

Cancer; Folate receptor; Folic acid; Imaging; Inflammation; PET; SPECT; Targeted radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; COPPER 64; COPPER 67; FLUORINE 18; FOLATE BINDING PROTEIN; FOLATE RECEPTOR; FOLATE RECEPTOR 1; FOLATE RECEPTOR 2; FOLIC ACID; GADOLINIUM; GALLIUM 66; GALLIUM 67; GALLIUM 68; INDIUM 111; IODINE 125; IRON OXIDE; LUTETIUM 177; NANOPARTICLE; PACLITAXEL; PENTETREOTIDE IN 111; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; SOMATOSTATIN DERIVATIVE; TECHNETIUM 99M; TETRAXETAN DEXTRO PHENYLALANINE 1 TYROSINE 3 OCTREOTIDE Y 90; TETRAXETAN TYROSINE 3 OCTREOTATE LU 177; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHELATION; CLICK CHEMISTRY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; EXTERNAL BEAM RADIOTHERAPY; FIELD EMISSION; GENE OVEREXPRESSION; HEMATOPOIETIC CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; IONIZING RADIATION; ISOTOPE LABELING; KIDNEY EPITHELIUM; LIPOSOMAL DELIVERY; MACROPHAGE; MACROPHAGE ACTIVATION; NEOPLASM; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; OSTEOARTHRITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY OF LIFE; RADIOACTIVITY; RHEUMATOID ARTHRITIS; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL; VITAMIN SUPPLEMENTATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; INFLAMMATION; MACROPHAGES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84857126850     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799315777     Document Type: Article

References (180)

1. Antony AC. Folate receptors. Annu Rev Nutr 1996; 16: 501-21.
2. Antony AC. The biological chemistry of folate receptors. Blood 1992; 79: 2807-20.
3. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005; 338: 284-93.
4. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008; 41: 120-29.
5. Turk MJ, Breur GJ, Widmer WR, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 2002; 46: 1947-55.
6. Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004; 56: 1205-17.
7. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992; 52: 3396-401.
8. Jansen FP, Vanderheyden JL. The future of SPECT in a time of PET. Nucl Med Biol 2007; 34: 733-35.
9. Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003; 10: 497-501.
10. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005; 46 Suppl 1: 67S-75S.
11. Ansquer C, Kraeber-Bodere F, Chatal JF. Current status and perspectives in peptide receptor radiation therapy. Curr Pharm Des 2009; 15: 2453-62.
12. Nanda PK, Lane SR, Retzloff LB, Pandey US, Smith CJ. Radiolabeled regulatory peptides for imaging and therapy. Curr Opin Endocrinol Diabetes Obes 2010; 17: 69-76.
13. Blom HJ, Shaw GM, den Heijer M, Finnell RH. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 2006; 7: 724-31.
14. Smulders YM, Stehouwer CD. Folate metabolism and cardiovascular disease. Semin Vasc Med 2005; 5: 87-97.
15. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Annu Rev Nutr 1999; 19: 91-122.
16. Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002; 367: 629-40.
17. Wang YH, Zhao RB, Goldman ID. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res 2004; 10: 6256-64.
18. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127: 917-28.
19. Zhao RB, Goldman ID. The molecular identity and characterization of a proton-coupled folate transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer and Metastasis Rev 2007; 26: 129-39.
20. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009; 11: e4.
21. Spiegelstein O, Eudy JD, Finnell RH. Identification of two putative novel folate receptor genes in humans and mouse. Gene 2000; 258: 117-25.
22. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992; 52: 6708-11.
23. + cells. Blood 1999; 93: 3940-48.
24. Ross JF, Wang H, Behm FG, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999; 85: 348-57.
25. Luhrs CA, Slomiany BL. A human membrane-associated folate binding protein is anchored by a glycosyl-phosphatidylinositol tail. J Biol Chem 1989; 264: 21446-49.
26. Elwood PC, Deutsch JC, Kolhouse JF. The conversion of the human membrane-associated folate binding protein (folate receptor) to the soluble folate binding protein by a membraneassociated metalloprotease. J Biol Chem 1991; 266: 2346-53.
27. Wang J, Shen F, Yan W, Wu M, Ratnam M. Proteolysis of the carboxyl-terminal GPI signal independent of GPI modification as a mechanism for selective protein secretion. Biochemistry 1997; 36: 14583-92.
28. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991; 51: 5329-38.
29. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26 - sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993; 142: 557-67.
30. Sun XL, Murphy BR, Li QJ, et al. Transduction of folate receptor cDNA into cervical carcinoma cells using recombinant adenoassociated virions delays cell proliferation in vitro and in vivo. J Clin Invest 1995; 96: 1535-47.
31. Figini M, Ferri R, Mezzanzanica D, et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 2003; 10: 1018-25.
32. Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009; 113: 438-46.
33. Tung CH, Lin YH, Moon WK, Weissleder R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem 2002; 3: 784-86.
34. Kennedy MD, Jallad KN, Thompson DH, Ben-Amotz D, Low PS. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 2003; 8: 636-41.
35. Moon WK, Lin YH, O'Loughlin T, et al. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug Chem 2003; 14: 539-45.
36. Chen WT, Mahmood U, Weissleder R, Tung CH. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. Arthritis Res Ther 2005; 7: R310-17.
37. Bharali DJ, Lucey DW, Jayakumar H, Pudavar HE, Prasad PN. Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J Am Chem Soc 2005; 127: 11364-71.
38. He W, Wang H, Hartmann LC, Cheng JX, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci USA 2007; 104: 11760-5.
39. Mindt TL, Müller C, Stuker F, et al. A click chemistry approach to the efficient synthesis of multiple imaging probes derived from a single precursor. Bioconjug Chem 2009; 20: 1940-9.
40. Konda SD, Aref M, Brechbiel M, Wiener EC. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest Radiol 2000; 35: 50-57.
41. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity fo late receptor expressed in ovarian tumor xenografts. MAGMA 2001; 12: 104-13.
42. Konda SD, Wang S, Brechbiel M, Wiener EC. Biodistribution of a 153Gd-folate dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian tumor xenografts. Invest Radiol 2002; 37: 199-204.
43. Choi H, Choi SR, Zhou R, Kung HF, Chen IW. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004;11: 996-1004.
44. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006; 78: 550-7.
45. Saborowski O, Simon GH, Raatschen HJ, et al. MR imaging of antigen-induced arthritis with a new, folate receptor-targeted contrast agent. Contrast Media Mol Imaging 2007; 2: 72-81.
46. Swanson SD, Kukowska-Latallo JF, Patri AK, et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine 2008; 3: 201-10.
47. Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev 2004; 56: 1143-60.
48. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008; 27: 655-64.
49. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009; 13: 256-62.
50. Milstein AB, Kennedy MD, Low PS, Bouman CA, Webb KJ. Statistical approach for detection and localization of a fluorescing mouse tumor in Intralipid. Appl Opt 2005; 44: 2300-10.
51. Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol 1997; 32: 748-54.
52. Chen WT, Thirumalai D, Shih TT, et al. Dynamic contrastenhanced folate-receptor-targeted MR imaging using a Gd-loaded PEG-dendrimer-folate conjugate in a mouse xenograft tumor model. Mol Imaging Biol 2010; 12: 145-54.
53. Salazar MD, Ratnam M. The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 2007; 26: 141-52.
54. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010; 53: 6811-24.
55. Leamon CP, Reddy JA. Folate-targeted chemotherapy. Adv Drug Deliv Rev 2004; 56: 1127-41.
56. Lee JW, Lu JY, Low PS, Fuchs PL. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorganic & Medicinal Chemistry 2002; 10: 2397-414.
57. Kamen BA, Smith AK. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 2004; 56: 1085-97.
58. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA 2006; 103: 13872-77.
59. Leamon CP, Reddy JA, Vlahov IR, et al. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007; 121: 1585-92.
60. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther 2007; 321: 462-68.
61. Leamon CP, Reddy JA, Vlahov IR, et al. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic. Bioconjug Chem 2005; 16: 803-11.
62. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP. Folate receptor specific anti-tumor activity of folatemitomycin conjugates. Cancer Chemother Pharmacol 2006; 58: 229-36.
63. Reddy JA, Westrick E, Santhapuram HK, et al. Folate Receptorspecific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 2007; 67: 6376-82.
64. Leamon CP, Reddy JA, Vlahov IR, Kleindl PJ, Vetzel M, Westrick E. Synthesis and biological evaluation of EC140: a novel folatetargeted vinca alkaloid conjugate. Bioconjug Chem 2006; 17: 1226-32.
65. Li J, Sausville EA, Klein PJ, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009; 49: 1467-76.
66. Sandoval RM, Kennedy MD, Low PS, Molitoris BA. Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol- Cell Physiol 2004; 287: C517-26.
67. Walton L. Preparation of a 125I-labelled conjugate of pteroylglutamic acid and its use in a radio ligand assay of folate in blood. Med Lab Sci 1981; 38: 187-95.
68. Antich P, Kulkarni PV, Constantinescu A, et al. Imaging of folate receptors with I-125 labeled folate using small animal imaging system built with plastic scintillating optical fibers. J Nucl Med 1994; 35: P222.
69. 67Ga-deferoxamine-folate, a potential radiopharmaceutical for tumor imaging. Bioconjug Chem 1996; 7: 56-62.
70. Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: effect of alternative conjugation chemistry. J Drug Target 1999; 7: 157-69.
71. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumor-selective radiopharmaceutical targeting via receptormediated endocytosis of gallium-67-deferoxamine-folate. J Nuc Med 1996; 37: 1003-08.
72. 67Ga-deferoxamine-folate to folate-receptorpositive human KB tumor xenografts. Nucl Med Biol 1999; 26: 23-5.
73. Jiang L, Zeng X, Wang Z, Chen Q. Cell line cross-contamination: KB is not an oral squamous cell carcinoma cell line. Eur J Oral Sci 2009; 117: 90-1.
74. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folatereceptor-targeted PET radiopharmaceuticals. Nucl Med Biol 2003; 30: 725-31.
75. 99mTc(CO)3-labeled N(tau)-histidine folate derivative with its isostructural, clicked 1,2,3-triazole analogue. Bioconjug Chem 2008; 19: 1689-95.
76. 68Ga for medical application. J Nucl Med 2007; 48: 1741-8.
77. 68Ga-PET: a powerful generatorbased alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008; 3: 67-77.
78. Fani M, Wang X, Nicolas G, et al. Development of new folatebased PET radiotracers: preclinical evaluation of Ga-DOTA-folate conjugates. Eur J Nucl Med Mol Imaging 2011; 38: 108-19.
79. 67Ga-DOTA-Bz-folate - investigations of methods to improve the tissue distribution of radiofolates. Nucl Med Biol 2011; 38: 715-23.
80. 99mTc-radiofolate. J Nucl Med 2008; 49: 310-17.
81. Mathias CJ, Wang S, Waters DJ, Turek JJ, Low PS, Green MA. Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med 1998; 39: 1579-85.
82. 111In]In-DTPA-folate, a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol 1998; 25: 585-7.
83. Mathias CJ, Green MA. Alternative kit formulations for compounding of 111In-DTPA-folate (folatescan). J Nucl Med 2000; 41: 1113.
84. Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In- DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003; 44: 700-7.
85. 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer. J Nucl Med 2008; 49: 623-9.
86. Brechbiel MW, Gansow OA, Atcher RW, et al. Synthesis of 1- (para-Isothiocyanatobenzyl) derivatives of DTPA and EDTA - Antibody labeling and tumor-imaging studies. Inorganic Chemistry 1986; 25: 2772-81.
87. Ke CY, Mathias CJ, Green MA. Synthesis and evaluation of an In- 111-labeled folate conjugate of octadentate DTPA. J Nucl ed 2000; 41: 232p.
88. Piscaer TM, Muller C, Mindt TL, et al. Imaging of activated macrophages in experimental osteoarthritis using folate targeted animal SPECT/CT. Arthritis Rheum 2011; 63: 1898-907.
89. Müller C, Mindt TL, de Jong M, Schibli R. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folatebased radionuclide therapy. Eur J Nucl Med Mol Imaging 2009; 36: 938-46.
90. 111In-DTPA conjugate of pteroic acid. J Am Chem Soc 2005; 20: 7421-6.
91. Purcell WT, Ettinger DS. Novel antifolate drugs. Curr Oncol Rep 2003; 5: 114-25.
92. Zhao RB, Gao F, Hanscom M, Goldman ID. A prominent low-pH methotrexate transport activity in human solid tumors: Contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004; 10: 718-27.
93. Zhao RB, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: Association with the presence of a secondary transport pathway. Cancer Res 2004; 64: 3313-9.
94. Theti DS, Jackman AL. The role of a-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004; 10: 1080-9.
95. Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994; 34: 397-419.
96. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folatedependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol 1995; 48: 459-71.
97. Mauritz R, Peters GJ, Kathmann I, et al. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. Cancer Chemother Pharmacol 2008; 62: 937-48.
98. Kane MA, Portillo RM, Elwood PC, Antony AC, Kolhouse JF. The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membraneassociated methotrexate binding protein. J Biol Chem 1986; 261:44-9.
99. Deutsch JC, Elwood PC, Portillo RM, Macey MG, Kolhouse JF. Role of the membrane-associated folate binding protein (folate receptor) in methotrexate transport by human KB cells. Arch Biochem Biophys 1989; 274: 327-37.
100. Jansen G, Westerhof GR, Kathmann I, Rademaker BC, Rijksen G, Schornagel JH. Identification of a membrane-associated folatebinding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance. Cancer Res 1989; 49: 2455-9.
101. Chung KN, Saikawa Y, Paik TH, et al. Stable transfectants of human MCF-7 breast-cancer cells with increased levels of the human folate receptor exhibit an increased sensitivity to antifolates. J Clin Invest 1993; 91: 1289-94.
102. Toffoli G, Corona G, Tolusso B, et al. Resistance to methotrexate in SKOV-3 cell lines after chronic exposure to carbamazepine is associated with a decreased expression of folate receptor. Int J Cancer 2000; 85: 683-90.
103. 111In-DTPA- methotrexate. Cancer Biother Radiopharm 1998; 13: 177-84.
104. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm 1998; 13: 427-35.
105. Wedeking PW, Wager RE, Arunachalam T, et al. Tweedle MFs; BRACCO INT BV (BRAC) BRACCO RES USA INC (BRAC) WEDEKING P W (WEDE-Individual) WAGER R E (WAGEIndividual) ARUNACHALAM T (ARUN-Individual) RAMALINGAM K (RAMA-Individual) LINDER K E (LINDIndividual) RANGANATHAN R S (RANG-Individual) NUNN A D (NUNN-Individual) RAJU N (RAJU-Individual) TWEEDLE M F (TWEE-Individual), assignee. Composition for diagnosis, therapy and radiotherapy contains folate receptor binding ligand. US patent WO9959640-A; EP1077729-A; WO9959640-A1; WO9959640-A3; WO9959640-A2; AU9936225-A; US6093382-A; EP1077729-A2; US6221334-B1; US2001004454-A1; JP2002515462-W; US7186397-B2; US2007077197-A1; US7399460-B2. WO9959640-A EP1077729-A WO9959640-A1 WO9959640-A2 25 Nov 1999 A61K-049/00 200010.
106. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 1999; 40: 1563-9.
107. 99mTc-labeled folate conjugates for folate receptor imaging. Nucl Med Biol 2011; 38: 557-65.
108. 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl Med Biol 1995; 22: 25-30.
109. 99mTechnetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 1999; 26: 389-96.
110. 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem 2005; 16: 1580-8.
111. Guo H, Xie F, Zhu M, et al. The synthesis of pteroyl-lys conjugates and its application as technetium-99m labeled radiotracer for folate receptor-positive tumor targeting. Bioorg Med Chem Lett 2011; 21: 2025-9.
112. Leamon CP, Cooper SR, Hardee GE. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 2003; 14: 738-47.
113. 99mTc-technetium(I)- and Re-rhenium(I)-folate derivatives for potential use in nuclear medicine. J Organometal Chem 2004; 689: 4712-21.
114. 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur J Nucl Med Mol Imaging 2006; 33: 1007-16.
115. 99mTc-Labeled small peptides as diagnostic radiopharmaceuticals. Chemical Rev 1999; 99: 2235-68.
116. 99mTc. Bioconjug Chem 1997; 8: 146-54.
117. 99mTc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem 2000; 11: 253-7.
118. 99mTcoxa- folate show uptake of both isomers in folate-receptor positive KB cell lines. J Nucl Med 2000; 41: 119p.
119. 99mTc-based radiopharmaceutical. Bioconjug Chem 2002; 13: 1200-10.
120. 99mTc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004; 45: 857-66.
121. 99mTc- EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008; 49: 899-906.
122. Matteson EL, Lowe VJ, Prendergast FG, et al. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 2009; 27: 253-9.
123. 99mTc-folate SPECT/CT. J Nucl Med 2010; 51: 1716-23.
124. 99mTc(CO)3-folates. Bioconjug Chem 2006; 17: 797-806.
125. Alberto R, Schibli R, Waibel R, Abram U, Schubiger AP. Basic aqueous chemistry of [M(OH2)3(CO)3]+ (M = Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev 1999; 192: 901-19.
126. 99mTcaquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999; 40: 1913-7.
127. 99mTc(I)- tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjug Chem 2000; 11: 345-51.
128. Alberto R, Schibli R, Egli A, et al. Metal carbonyl syntheses. XXII. Low-pressure carbonylation of [MOCl4]- and [MO4]-. The technetium(I) and rhenium(I) complexes [NEt4]2[MCl3(CO)3]. J Organometal Chem 1995; 492: 217-24.
129. 99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 1998; 120: 7987-8.
130. Schibli R, Schubiger PA. Current use and future potential of organometallic radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2002; 29: 1529-42. [131]
131. 99mTc(CO)3-DTPA-folate as a folate-receptor-targeted radiopharmaceutical. Nucl Med Biol 2002; 29: 569-73.
132. 188Re: a potential strategyfor diagnosis and therapy of folate receptor-positive tumors. NuclMed Biol 2007; 34: 595-601.
133. 188Re. Synthesis-Stuttgart 2009: 787-92.
134. Holm J, Hansen SI, Hoier-Madsen M, Bostad L. High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneityand hydrophobic domain of the binding protein. Biochem J 1991; 280 (Pt 1): 267-71.
135. Müller C, Brühlmeier M, Schubiger AP, Schibli R. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo. J Nucl Med 2006; 47: 2057-64.
136. Mindt TL, Struthers H, Brans L, et al. Click to chelate: synthesis and installation of metal chelates into biomolecules in a single step. J Am Chem Soc 2006; 128: 15096-7.
137. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl 2001; 40: 2004-21.
138. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov Today 2003; 8: 1128-37.
139. Bettio A, Honer M, Müller C, et al. Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. J Nucl Med 2006; 47: 1153-60.
140. Dolle F. Fluorine-18-labelled fluoropyridines: advances in radiopharmaceutical design. Curr Pharm Des 2005; 11: 3221-35.
141. Barentsz J, Takahashi S, Oyen W, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 2006; 24: 3234-44.
142. Iagaru AH, Mittra ES, McDougall IR, Quon A, Gambhir SS. 18FFDG PET/CT evaluation of patients with ovarian carcinoma. Nucl Med Commun 2008; 29: 1046-51.
143. Kubota K, Ito K, Morooka M, et al Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 2009; 23: 783-91.
144. Ross TL, Honer M, Lam PYH, et al. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative. Bioconjug Chem 2008; 19: 2462-70.
145. 18F]fluoropeptides using CuI catalyzed 1,3-dipolar cycloaddition. Tetrahedron Letters 2006; 47: 6681-4.
146. 18F-labeled folic acid derivative with improved properties for the PET imaging of folate receptor-positive tumors. J Nucl Med 2010; 51: 1756-62.
147. 99mTc-radiofolate uptake in tumors and kidneys. Nucl Med Biol 2007; 34: 603-8.
148. Nakashima-Matsushita N, Homma T, Yu S, et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 1609-16.
149. Buiting AM, Zhou F, Bakker JA, van Rooijen N, Huang L. Biodistribution of clodronate and liposomes used in the liposome mediated macrophage 'suicide' approach. J Immunol Methods 1996; 192: 55-62.
150. Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther 2006; 8: R77.
151. Yanni G, Whelan A, Feighery C, Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 39-44.
152. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39: 115-24.
153. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997; 40: 217-25.
154. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2: 189-202.
155. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 2002; 51: 153-62.
156. Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against haptendecorated cancer cells. Int J Cancer 2005; 116: 710-9.
157. Lu Y, Xu LC, Parker N, et al. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugatetargeted immunotherapy in hapten-immunized mice. Mol Cancer Ther 2006; 5: 3258-67.
158. Lu Y, Klein PJ, Westrick E, et al. Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer. AAPS J 2009; 11: 628-38.
159. Antohe F, Radulescu L, Puchianu E, Kennedy MD, Low PS, Simionescu M. Increased uptake of folate conjugates by activated macrophages in experimental hyperlipemia. Cell Tissue Res 2005; 320: 277-85.
160. Ayala-Lopez W, Xia W, Varghese B, Low PS. Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J Nucl Med 2010; 51: 768-74.
161. Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-17.
162. 0]octreotide in patients. Eur J Nucl Med 2001; 28: 1319-25.
163. 3]octreotate. J Clin Oncol 2004; 22: 2724-9.
164. 3]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33: 1346-51.
165. McMartin KE, Morshed KM, Hazenmartin DJ, Sens DA. Folate transport and binding by cultured human proximal tubule cells. Am J Physiol 1992; 263: F841-F848.
166. Cooperman JM, Pesci-Bourel A, Luhby AL. Urinary excretion of folic acid activity in man. Clin Chem 1970; 16: 375-81.
167. Selhub J, Emmanouel D, Stavropoulos T, Arnold R. Renal folate absorption and the kidney folate binding protein. I. Urinary clearance studies. Am J Physiol 1987; 252: F750-6.
168. Birn H, Spiegelstein O, Christensen EI, Finnell RH. Renal tubular reabsorption of folate mediated by folate binding protein 1. J Am Soc Nephrol 2005; 16: 608-15.
169. Hjelle JT, Christensen EI, Carone FA, Selhub J. Cell fractionation and electron-microscope studies of kidney folate-binding rotein. Am J Physiol 1991; 260: C338-46.
170. Mogensen CE, Solling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977; 37: 477-86.
171. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993; 67: 1437-9.
172. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996; 37: 1388-92.
173. Bernard BF, Krenning EP, Breeman WA, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997; 38: 1929-33.
174. Behe M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005; 46: 1012-5.
175. McHugh M, Cheng YC. Demonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cells. J Biol Chem 1979; 254: 1312-8.
176. Jansen G, Kathmann I, Rademaker BC, et al. Expression of a folate binding-protein in L1210 cells grown in low folate medium. Cancer Res 1989; 49: 1959-63.
177. Miotti S, Facheris P, Tomassetti A, Bottero F, et al. Growth of ovarian-carcinoma cell-lines at physiological folate concentration - effect on folate-binding Protein expression in-vitro and in-vivo. Int J Cancer 1995; 63: 395-401.
178. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24: 37-77.
179. Wang S, Luo J, Lantrip DA, et al. Design and synthesis of[111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjug Chem 1997; 8: 673-9.
180. 111In-DTPA conjugate of pteroic acid. J Am Chem Soc 2005; 127: 7421-6.